MARKET

CRL

CRL

Charles River Lb
NYSE

Real-time Quotes | Nasdaq Last Sale

419.65
-12.83
-2.97%
Opening 14:58 09/28 EDT
OPEN
426.28
PREV CLOSE
432.47
HIGH
427.48
LOW
412.89
VOLUME
328.73K
TURNOVER
--
52 WEEK HIGH
460.21
52 WEEK LOW
219.09
MARKET CAP
21.15B
P/E (TTM)
54.17
1D
5D
1M
3M
1Y
5Y
Mice Model Market 2021-2025: Industry Analysis, Market Trends, Market Growth, Opportunities & Forecast
The is segmented on the lines of its technology, service, type, application, mild care product type and regional. Based on technology segmentation it covers CRISPR, microinjection, embryonic stem cell injection, nuclear transfer, other technologies (Genet...
Heraldkeepers · 6d ago
Donoghue Forlines Momentum Fund Buys Bruker Corp, Charles River Laboratories International Inc, ...
GuruFocus News · 6d ago
Charles River Launches First Annual Healthcare Collaboration Report
WILMINGTON, Mass., September 20, 2021--The Healthcare Collaboration Report polled more than 1,500 Americans about the current state of healthcare, drug development, and pandemic prevention.
Business Wire · 09/20 12:00
Bny Mellon Stock Index Fund, Inc. Buys Charles River Laboratories International Inc, PTC Inc, ...
GuruFocus News · 09/17 12:38
7 Best Small Cap Stocks to Buy Heading Into Q4
Investor Place · 09/15 20:19
Great-west Funds Inc Buys Charles River Laboratories International Inc, PTC Inc, Huntington ...
GuruFocus News · 09/15 17:38
Insider Sell: Charles River Laboratories International
MT Newswires · 09/15 11:19
Here's Why You Should Invest in Charles River (CRL) Now
Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.
Zacks · 09/14 13:44
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRL. Analyze the recent business situations of Charles River Lb through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

38.46%Strong Buy
53.85%Buy
7.69%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CRL stock price target is 450.55 with a high estimate of 485.00 and a low estimate of 354.00.
High485.00
Average450.55
Low354.00
Current 419.82
EPS
Actual
Estimate
0.651.301.962.61
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 777
Institutional Holdings: 51.11M
% Owned: 101.41%
Shares Outstanding: 50.40M
TypeInstitutionsShares
Increased
211
5.12M
New
120
912.70K
Decreased
219
4.93M
Sold Out
46
595.89K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.72%
Pharmaceuticals & Medical Research
-1.35%
Key Executives
Chairman/President/Chief Executive Officer/Director
James Foster
Chief Financial Officer/Executive Vice President
David Smith
Executive Vice President
William Barbo
Executive Vice President
Birgit Girshick
Executive Vice President
Joseph LaPlume
Lead Director/Independent Director
George Milne
Independent Director
Nancy Andrews
Independent Director
Robert Bertolini
Independent Director
Deborah Kochevar
Independent Director
George Llado
Independent Director
Martin Mackay
Independent Director
George Massaro
Independent Director
Richard Reese
Independent Director
Richard Wallman
Independent Director
Virginia Wilson
No Data
  • All
  • Financials
  • Insiders
More
About CRL
Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices, and therapies. The Company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment includes the Research Models, Research Model Services, and Research Products businesses. The DSA segment includes services required to take a drug through the early development process including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions, Biologics Solutions, and Avian Vaccine Services.

Webull offers kinds of Charles River Laboratories Intl. Inc stock information, including NYSE:CRL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRL stock methods without spending real money on the virtual paper trading platform.